Palifren Long (Paliperidone)

Paliperidone, the active ingredient in Palifren Long, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is employed in the maintenance treatment of schizophrenia in adult patients. GNH USA supplies Palifren Long as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Palifren Long as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone is indicated for the management of schizophrenia, a chronic psychotic disorder affecting thought, perception and behavior.

- Schizophrenia: Reduces risk of relapse and helps maintain symptom control when used as a long‑acting injection. - Schizoaffective disorder: Provides sustained antipsychotic coverage to stabilize mood and psychotic symptoms. - Bipolar I disorder (maintenance): Offers adjunctive long‑term control of manic episodes when other therapies are insufficient.

Palifren Long may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema - Headache - Dizziness or light‑headedness - Fatigue - Nausea - Restlessness (akathisia)

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia or new‑onset diabetes - Seizures - Elevated prolactin leading to galactorrhoea or menstrual disturbances

When prescribing Palifren Long, clinicians should assess patient history and monitor for specific safety concerns.

- Cardiovascular assessment: Evaluate for QT‑interval prolongation and orthostatic hypotension. - Metabolic monitoring: Check blood glucose and lipid profiles periodically. - Movement disorders: Observe for signs of tardive dyskinesia or akathisia. - Hormonal effects: Monitor prolactin levels, especially in women of childbearing age. - Pregnancy and lactation: Use only if benefits outweigh potential risks. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Palifren Long can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase paliperidone exposure. - Strong CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce therapeutic levels. - QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive orthostatic hypotension. - CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation. - Anticholinergic drugs: may worsen cognitive side effects. - Lithium: potential for increased neuro‑toxic effects. - NSAIDs: may raise risk of bleeding when combined with anticoagulants.